Advertisement

Anticancer Immunotherapy: Prospects and Challenges

  • Ruchi Sachdeva
  • Poonam Singh
  • Anjali Bose
  • Beneeta Kalha
  • Moumita Sarkar
  • Rahul PalEmail author
Chapter

Abstract

Accumulating evidence indicates that immune cells in the microenvironment play a significant role in tumor progression. Understanding the dynamic interplay between tumor cells and the host immune system is therefore of critical importance. While some immunotherapeutic strategies aim to specifically overcome hyporesponsiveness to tumor-associated antigens, others seek to nonspecifically activate the immune system; efficacy and toxicity are overriding, and often conflicting, concerns. This chapter, while occasionally providing brief historical perspectives, describes ongoing efforts in the area, including strategies for anticancer vaccination and adoptive cell transfer, the use of cytokines and development of oncolytic viruses, and the administration of checkpoint inhibitors. While significant successes have been achieved, the field is also characterized by notable failure, an indication that much remains unknown about factors that trigger and promote tumorigenesis, about current limitations in the effective delivery of therapeutic moieties, and about the workings of the immune system.

Keywords

Immunotherapy Tumor-associated antigens Vaccines Chemotherapy Adoptive cell therapy Oncolytic viruses 

References

  1. Abate-Daga D, Lagisetty KH, Tran E, Zheng Z, Gattinoni L, Yu Z, Burns WR, Miermont AM, Teper Y, Rudloff U, Restifo NP, Feldman SA, Rosenberg SA, Morgan RA (2014) A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther 25:1003–1012PubMedPubMedCentralCrossRefGoogle Scholar
  2. Acevedo HF, Raikow RB, Powell JE, Stevens VC (1987) Effects of immunization against human choriogonadotropin on the growth of transplanted Lewis lung carcinoma and spontaneous mammary adenocarcinoma in mice. Cancer Detect Prev Suppl 1:477–486PubMedGoogle Scholar
  3. Adachi K, Tamada K (2015) Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci 106:945–950PubMedPubMedCentralCrossRefGoogle Scholar
  4. Adamus T, Kortylewski M (2018) The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn) 22:56–60Google Scholar
  5. Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M (2014) Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med 6:261ra151.  https://doi.org/10.1126/scitranslmed.3010162CrossRefPubMedPubMedCentralGoogle Scholar
  6. Ahmadzadeh M, Rosenberg SA (2006) IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients. Blood 107:2409–2414PubMedPubMedCentralCrossRefGoogle Scholar
  7. Alam A, Singh O, Talwar GP (1989) Stability of an antifertility vaccine consisting of gonadotropin subunits linked to tetanus toxoid. Vaccine 7:129–131PubMedCrossRefGoogle Scholar
  8. Alkayyal AA, Mahmou AB, Auer RC (2016) Interleukin-12-expressing oncolytic virus: A promising strategy for cancer immunotherapy. J Taibah Univ Med Sci 11:187–193Google Scholar
  9. Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561.  https://doi.org/10.3389/fphar.2017.00561CrossRefPubMedPubMedCentralGoogle Scholar
  10. Anderson BD, Nakamura T, Russell SJ, Peng K-W (2004) High CD-46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 64:4919–4926PubMedCrossRefGoogle Scholar
  11. Andreasen PA, Egelund R, Petersen HH (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57:25–40PubMedCrossRefGoogle Scholar
  12. Andtbacka RHI, Collichio FA, Amatruda T, Senzer NN, Chesney J, Delman KA (2013) OPTiM: a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. J Clin Oncol 31:18_suppl, LBA9008-LBA9008CrossRefGoogle Scholar
  13. Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33:2780–2788PubMedCrossRefGoogle Scholar
  14. Ang WX, Zhao Y, Kwang T, Wu C, Chen C, Toh HC, Mahendran R, Esuvaranathan K, Wang S (2016) Local immune stimulation by intravesical instillation of baculovirus to enable bladder cancer therapy. Sci Rep 8(6):27455.  https://doi.org/10.1038/srep27455CrossRefGoogle Scholar
  15. Atkins MB, Regan M, McDermott D (2004) Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 10:6342S–6346SPubMedCrossRefGoogle Scholar
  16. Aurisicchio L, Peruzzi D, Conforti A, Dharmapuri S, Biondo A, Giampaoli S, Fridman A, Bagchi A, Winkelmann CT, Gibson R, Kandimalla ER, Agrawal S, Ciliberto G, La Monica N (2009) Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res 15:1575–1584PubMedCrossRefGoogle Scholar
  17. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BW, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol 71:447–461PubMedCrossRefGoogle Scholar
  18. Barber GN (2011) Cytoplasmic DNA innate immune pathways. Immunol Rev 243:99–108PubMedCrossRefGoogle Scholar
  19. Bauer S, Wagner H (2002) Bacterial CpG-DNA licenses TLR9. Curr Top Microbiol Immunol 270:145–154PubMedGoogle Scholar
  20. Berenson JR, Einstein AB Jr, Fefer A (1975) Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells. J Immunol 115:234–238PubMedGoogle Scholar
  21. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A (2008) Phase I safety and pharmacokinetic study of CT- 011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14:3044–3051PubMedCrossRefGoogle Scholar
  22. Berinstein NL (2007) Enhancing cancer vaccines with immunomodulators. Vaccine 25(Suppl 2):B72–B88PubMedCrossRefGoogle Scholar
  23. Berndt S, Perrier d’Hauterive S, Blacher S, Péqueux C, Lorquet S, Munaut C, Applanat M, Hervé MA, Lamandé N, Corvol P, van den Brûle F, Frankenne F, Poutanen M, Huhtaniemi I, Geenen V, Noël A, Foidart JM (2006) Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium. FASEB J. 20:2630–2632PubMedCrossRefGoogle Scholar
  24. Berraondo P, Etxeberria I, Ponz-Sarvise M, Melero I (2018) Revisiting interleukin-12 as a cancer immunotherapy agent. Clin Cancer Res 24:2716–2718PubMedCrossRefGoogle Scholar
  25. Beyersdorf N, Kerkau T, Hünig T (2015) CD28 co-stimulation in T-cell homeostasis: a recent perspective. Immunotargets Ther 4:111–122PubMedPubMedCentralGoogle Scholar
  26. Bhatia S, Curti B, Ernstoff M, Gordon M, Heath E, Miller W, Puzanov I, Quinn D, Flaig T, Veldhuizen P, Byrnes-Blake K, Freeman J, Bittner R, Hunder N, Souza S, John A, Thompson J (2014) Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer 2:2.  https://doi.org/10.1186/2051-1426-2-2CrossRefPubMedPubMedCentralGoogle Scholar
  27. Bilsen MP, van Meijgaarden KE, de Jong HK, Joosten SA, Prins C, Kroft LJM, Jonker JT, Crobach S, Pelger RC, Ottenhoff THM, Arend SM (2018) A novel view on the pathogenesis of complications after intravesical BCG for bladder cancer. Int J Infect Dis 72:63–68PubMedCrossRefGoogle Scholar
  28. Bollard CM, Aguilar L, Straathof KC (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin’s disease. J Exp Med 200:1623–1633PubMedPubMedCentralCrossRefGoogle Scholar
  29. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ (2016) Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 20(3):16011.  https://doi.org/10.1038/mto.2016.11CrossRefGoogle Scholar
  30. Bose A, Huhtaniemi I, Singh O, Pal R (2013) Synergistic activation of innate and adaptive immune mechanisms in the treatment of gonadotropin-sensitive tumors. PLoS One 8(4):e61288PubMedPubMedCentralCrossRefGoogle Scholar
  31. Boviatsis EJ, Park JS, Sena-Esteves M, Kramm CM, Chase M, Efird JT, Wei MX, Breakefield XO, Chiocca EA (1994) Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 54:5745–5751PubMedGoogle Scholar
  32. Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, Brunelliѐre J, Bramson JL, Lichty BD, Wan Y (2010) Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 18:1430–1439PubMedPubMedCentralCrossRefGoogle Scholar
  33. Buchbinder EI, Desai A (2016) CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39:98–106PubMedPubMedCentralCrossRefGoogle Scholar
  34. Buchbinder EI, Dutcher JP, Perritt JC, Clark J, Holtan SG, Kirkwood JM, Brendan D, Curti BD, Lao CD, Kaufman H, Fishman MN, McDermott DF (2016) A prospective analysis of high-dose interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 34:15_suppl.e21006CrossRefGoogle Scholar
  35. Bucheit AD, Kumar S, Grote DM, Lin Y, von Messling V, Cattaneo RB, Fielding AK (2003) An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 7:62–72PubMedCrossRefGoogle Scholar
  36. Burga RA, Thorn M, Point GR, Guha P, Nguyen CT, Licata LA, DeMatteo RP, Ayala A, Joseph EN, Junghans RP, Katz SC (2015) Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother 64:817–829PubMedPubMedCentralCrossRefGoogle Scholar
  37. Callahan MK, Postow MA, Wolchok JD (2016) Targeting T cell co-receptors for cancer therapy. Immunity 44:1069–1078PubMedCrossRefGoogle Scholar
  38. Carralot JP, Weide B, Schoor O, Probst J, Scheel B, Teufel R, Hoerr I, Garbe C, Rammensee HG, Pascolo S (2005) Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. Genet Vaccines Ther 3:6.  https://doi.org/10.1186/1479-0556-3-6CrossRefPubMedPubMedCentralGoogle Scholar
  39. Chan E, Kwak EL, Hwang J, Heiskala M, de La Bourdonnaye G, Mita M (2015) Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease. Cancer Chemother Pharmacol 75:701–709PubMedCrossRefGoogle Scholar
  40. Chawla-Sarkar M, Leaman DW, Borden EC (2001) Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: Correlation with TRAIL/Apo2l induction in melanoma cell lines. Clin Cancer Res 7:1821–1831PubMedGoogle Scholar
  41. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC (2003) Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8:237–249PubMedCrossRefGoogle Scholar
  42. Chonghaile TN, Letai A (2008) Mimicking the BH3 domain to kill cancer cells. Oncogene 27(Suppl 1):S149–S157.  https://doi.org/10.1038/onc.2009.52CrossRefPubMedCentralPubMedGoogle Scholar
  43. Cohen JI (2015) Epstein-barr virus vaccines. Clin Transl Immunol 4:e32.  https://doi.org/10.1038/cti.2014.27CrossRefGoogle Scholar
  44. Cole LA (2012) HCG variants, the growth factors which drive human malignancies. Am J Cancer Res 2:22–35PubMedGoogle Scholar
  45. Cole DJ, Weil DP, Shilyansky J, Custer M, Kawakami Y, Rosenberg SA, Nishimura MI (1995) Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 55:748–752PubMedGoogle Scholar
  46. Colombetti S, Levy F, Chapatte L (2009) IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector. Blood 113:6629–6637PubMedCrossRefGoogle Scholar
  47. Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, Foster AE (2010) Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 33:780–788PubMedPubMedCentralCrossRefGoogle Scholar
  48. Cutts FT, Hall AJ (2004) Vaccines for neonatal viral infections: hepatitis B vaccine. Expert Rev Vaccines 3:349–352PubMedCrossRefGoogle Scholar
  49. Da Gama DJ, Parakh S, Andrews MC, Woods K, Pasam A, Tutuka C, Ostrouska S, Blackburn JM, Behren A, Cebon J (2018) Autoantibodies may predict immune-related toxicity: results from a Phase I study of intralesional Bacillus Calmette-Guérin followed by ipilimumab in patients with advanced metastatic melanoma. Front Immunol 9:411.  https://doi.org/10.3389/fimmu.2018.00411CrossRefGoogle Scholar
  50. Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25.  https://doi.org/10.1126/scitranslmed.3008226CrossRefPubMedPubMedCentralGoogle Scholar
  51. Delforme EJ, Alexander P (1964) Treatment of primary fibrosarcoma in the rat with immune lymphocyte. Lancet 2:117–120CrossRefGoogle Scholar
  52. Dharmapuri S, Aurisicchio L, Neuner P, Verdirame M, Ciliberto G, La Monica N (2009) An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models. Cancer Gene Ther 16:462–472PubMedCrossRefGoogle Scholar
  53. Di Carlo E, Comes A, Basso S, De Ambrosis A, Meazza R, Musiani P, Moelling K, Albini A, Ferrini S (2000) The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement. J Immunol 165:3111–3118PubMedCrossRefGoogle Scholar
  54. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365:1673–1683PubMedPubMedCentralCrossRefGoogle Scholar
  55. Ding ZC, Habtetsion T, Cao Y, Li T, Liu C, Kuczma M, Chen T, Hao Z, Bryan L, Munn DH, Zhou G (2017) Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells. Sci Rep 7:12168.  https://doi.org/10.1038/s41598-017-12488-zCrossRefPubMedPubMedCentralGoogle Scholar
  56. Disis ML, Cheever MA (1996) Oncogenic proteins as tumor antigens. Curr Opin Immunol 8:632–642CrossRefGoogle Scholar
  57. Doorbar J (2006) Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond) 110:525–541CrossRefGoogle Scholar
  58. Dotti G, Gottschalk S, Savoldo B, Brenner MK (2014) Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257:107–126PubMedCrossRefGoogle Scholar
  59. Douglas J, Sharp A, Chau C, Head J, Drake T, Wheater M, Geldart T, Mead G, Crabb SJ (2014) Serum total hCGβ level is an independent prognostic factor in transitional cell carcinoma of the urothelial tract. Br J Cancer 110:1759–1766PubMedPubMedCentralCrossRefGoogle Scholar
  60. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 90:3539–3543PubMedCrossRefGoogle Scholar
  61. Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, Limacher JM, Squiban P, Pantuck A (2009) MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 27:379–386PubMedCrossRefGoogle Scholar
  62. Du X, Tang F, Liu M, Su J, Zhang Y, Wu W, Devenport M, Lazarski CA, Zhang P, Wang X, Ye P, Wang C, Hwang E, Zhu T, Xu T, Zheng P, Liu Y (2018) A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res 28:416–432PubMedPubMedCentralCrossRefGoogle Scholar
  63. Braunstein GD (1996) Evidence favoring human chorionic gonadotropin as the physiological ‘rescuer’of the corpus luteum during early pregnancy. Early Pregnancy 2:183–190PubMedGoogle Scholar
  64. Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, Daphtary MM, Biedrzycki B, Wolff AC, Stearns V, Disis ML, Ye X, Piantadosi S, Fetting JH, Davidson NE, Jaffee EM (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27:5911–5918PubMedPubMedCentralCrossRefGoogle Scholar
  65. Engeland CE, Grossardt C, Veinalde R, Bossow S, Lutz D, Kaufmann JK, Shevchenko I, Umansky V, Nettelbeck DM, Weichert W, Jӓger D, Kalle C, Ungerechts G (2014) CTLA-4 and PD-L1 Checkpoint blockade enhances oncolytic measles virus therapy. Mol Ther 22:1949–1959PubMedPubMedCentralCrossRefGoogle Scholar
  66. Escudier B, Farace F, Angevin E, Charpentier F, Nitenberg G, Triebel F, Hercend T (1994) Immunotherapy with interleukin-2 (IL2) and lymphokine-activated natural killer cells: improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. Eur J Cancer 30A:1078–1083PubMedCrossRefGoogle Scholar
  67. Eshhar Z, Waks T, Gross G, Schindler DG (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad USA 90:720–724CrossRefGoogle Scholar
  68. Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L, Costantini M, Scarpi E, Amadori D, Ridolfi R (2012) Ipilimumab in advanced melanoma: reports of long-lasting responses. Melanoma Res 22:263–270PubMedCrossRefGoogle Scholar
  69. Farsaci B, Sabzevari H, Higgins JP, Di BMG, Takai S, Schlom J, Hodge JW (2010) Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer 127:1603–1613PubMedPubMedCentralCrossRefGoogle Scholar
  70. Fedorov VD, Themeli M, Sadelain M (2013) PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med 5:215ra172.  https://doi.org/10.1126/scitranslmed.3006597CrossRefPubMedPubMedCentralGoogle Scholar
  71. Figlin RA, Amin A, Dudek A, Logan T, Lance RS, Holzbeierlein JM, Sumanta Kumar Pal M, Gamble AH, DeBenedette M, Tcherepanova IY, Williams WL, Plessinger D, Miesowicz F, Nicolette CA (2012) Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC). J Clin Oncol 30(Suppl):a348CrossRefGoogle Scholar
  72. Williamson NR, Fineran PC, Gristwood T, Chawrai SR, Leeper FJ, Salmond GP (2007) Anticancer and immunosuppressive properties of bacterial prodiginines. Future Microbiol 2:605–618PubMedCrossRefGoogle Scholar
  73. Finstad CL, Wang CY, Kowalski J, Zhang M, Li ML, Li XM, Xia WG, Bosland MC, Murthy KK, Walfield AM, Koff WC, Zamb TJ (2004) Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy. Vaccine 22:1300–1313PubMedCrossRefGoogle Scholar
  74. Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM, Kallen KJ (2012) Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med 14:428–439PubMedCrossRefGoogle Scholar
  75. Frazer IH, Lowy DR, Schiller JT (2007) Prevention of cancer through immunization: Prospects and challenges for the 21st century. Eur J Immunol 37(Suppl1):S148–S155PubMedCrossRefGoogle Scholar
  76. Friesel R, Komoriya A, Maciag T (1987) Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 104:689–696PubMedCrossRefGoogle Scholar
  77. Fuge O, Vasdev N, Allchorne P, James SAG (2015) Immunotherapy for bladder cancer. Res Rep Urol 7:65–79PubMedPubMedCentralGoogle Scholar
  78. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng K-W, Russell SJ (2010) Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 70(3):875–882PubMedPubMedCentralCrossRefGoogle Scholar
  79. Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW (2011) Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother 60:1227–1242PubMedPubMedCentralCrossRefGoogle Scholar
  80. Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA (2015) Chimeric antigen receptor t cells against cd19 for multiple myeloma. N Engl J Med 373:1040–1047PubMedPubMedCentralCrossRefGoogle Scholar
  81. Garg M, Chaurasiya D, Rana R, Jagadish N, Kanojia D, Dudha N, Kamran N, Salhan S, Bhatnagar A, Suri S, Gupta A, Suri A (2007) Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Clin Cancer Res 13:1421–1428PubMedCrossRefGoogle Scholar
  82. Garg M, Kanojia D, Salhan S, Suri S, Gupta A, Lohiya NK, Suri A (2009) Sperm-associated antigen 9 is a biomarker for early cervical carcinoma. Cancer 115:2671–2683PubMedCrossRefGoogle Scholar
  83. Gattinoni L, Finkelstein SE, Klebanoff CA, Antony PA, Palmer DC, Spiess PJ, Hwang LN, Yu Z, Wrzesnski C, Heimann DM, Surh CD, Rosenberg SA, Restifo NP (2005) Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 202:907–912PubMedPubMedCentralCrossRefGoogle Scholar
  84. Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L, Marra E, Roscilli G, Ciliberto G, Aurisicchio L (2013) Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Hum Gene Ther 24:728–738PubMedPubMedCentralCrossRefGoogle Scholar
  85. Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F, Pezzella G, Borsellino N, Durini E, Valenza R, Agostara B, Colucci G, Gruppo OIM (2008) Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M (Gruppo Oncologico Italia Meridionale). Lung Cancer 61:369–377PubMedCrossRefGoogle Scholar
  86. Geiger TL, Nguyen P, Leitenberg D, Flavell RA (2001) Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes. Blood 98:2364–2371PubMedCrossRefGoogle Scholar
  87. Gettinger SN, Shepherd FA, Antonia SJ, Brahmer JR, Man Chow LQ, Juergens RA, Borghaei H, Shen Y, Harbison C, Alaparthy S, Chen AC, Rizvi NA (2014) First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status. J Clin Oncol 32:15_suppl,8024-8024Google Scholar
  88. Gillott DJ, Iles RK, Chard T (1996) The effects of beta-human chorionic gonadotropin on the in vitro growth of bladder cancer cell lines. Br J Cancer 73:323–326PubMedPubMedCentralCrossRefGoogle Scholar
  89. Giri DK, Jayaraman S, Neelaram GS, Jayashankar R, Talwar GP (1991) Prostatic hypoplasia in bonnet monkeys following active immunization with semisynthetic anti-LHRH vaccine. Exp Mol Pathol 54:255–264PubMedCrossRefGoogle Scholar
  90. Greenland JR, Letvin NL (2007) Chemical adjuvants for plasmid DNA vaccines. Vaccine 25:3731–3741PubMedCrossRefGoogle Scholar
  91. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH (2013) Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368:1509–1518PubMedPubMedCentralCrossRefGoogle Scholar
  92. Gu YZ, Fan CW, Lu R, Shao B, Sang YX, Huang QR, Li X, Meng WT, Mo XM, Wei YQ (2016) Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity. Sci Rep 6:32351.  https://doi.org/10.1038/srep32351CrossRefPubMedPubMedCentralGoogle Scholar
  93. Hammers HJ, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF, Razak ARA, Pal SK, Voss MH, Sharma P, Kollmannsberger CK, Daniel Heng YC, Spratlin JL, Shen Y, Kurland JF, Gagnier P, Amin A (2014) Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol 32:15_suppl, 4504-4504CrossRefGoogle Scholar
  94. Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, Kingsman SM, Naylor S, Griffiths R, Steven N, Hawkins RE (2008) Vaccination of colorectal cancer a patient with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother 57:977–986PubMedCrossRefGoogle Scholar
  95. Hawkins RE, Macdermott C, Shablak A, Hamer C, Thistlethwaite F, Drury NL, Chikoti P, Shingler W, Naylor S, Harrop R (2009) Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha. J Immunother 32:424–429PubMedCrossRefGoogle Scholar
  96. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, Kershaw MH, Smyth MJ, Darcy PK (2002) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 100:3155–3163PubMedCrossRefGoogle Scholar
  97. He H, Wisner P, Yang G, Hu HM, Haley D, Miller W, O’Hara A, Alvord WG, Clegg CH, Fox BA, Urba WJ, Walker EB (2006) Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med 4:24.  https://doi.org/10.1186/1479-5876-4-24CrossRefPubMedPubMedCentralGoogle Scholar
  98. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, Zhang YJ, Baskin DS, Merchant FA, Brawley VS, Byrd TT, Krebs S, Wu MF, Liu H, Heslop HE, Gottschalk S, Yvon E, Ahmed N (2013) Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 21:2087–2101PubMedPubMedCentralCrossRefGoogle Scholar
  99. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, Shepherd FA, Laurie SA, Geese WJ, Agrawal S, Young TC, Li X, Antonia SJ (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18:31–41PubMedCrossRefGoogle Scholar
  100. Hérin M, Lemoine C, Weynants P, Vessière F, Van Pel A, Knuth A, Devos R, Boon T (1987) Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer 39:390–396PubMedCrossRefGoogle Scholar
  101. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, Bollard CM, Liu H, Wu MF, Rochester RJ, Amrolia PJ, Hurwitz JL, Brenner MK, Rooney CM (2010) Long term outcome of EBV specific T cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115:925–935PubMedPubMedCentralCrossRefGoogle Scholar
  102. Hida T, Kaji R, Satouchi M, Ikeda N, Horiike A, Nokihara H, Seto T, Kawakami T, Nakagawa S, Kubo T (2018) Atezolizumab in Japanese patients with previously treated advanced non–small-cell lung cancer: a subgroup analysis of the Phase 3 OAK study. Clin Lung Cancer 19(4):e405–e415.  https://doi.org/10.1016/j.cllc.2018.01.004CrossRefPubMedGoogle Scholar
  103. Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP (2009) Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A 106:17469–17474PubMedPubMedCentralCrossRefGoogle Scholar
  104. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab patients with metastatic melanoma. N Engl J Med 363:711–723PubMedPubMedCentralCrossRefGoogle Scholar
  105. Hsu CT, Ting CY, Ting CJ, Chen TY, Lin CP, Whang-Peng J, Hwang J (2000) Vaccination against gonadotropin-releasing hormone (GnRH) using toxin receptor-binding domain-conjugated GnRH repeats. Cancer Res 60:3701–3705PubMedGoogle Scholar
  106. Hsueh EC, Gupta RK, Qi K, Morton DL (1998) Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16:2913–2920PubMedCrossRefGoogle Scholar
  107. Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, Wang FC, Lorch JH (2017) Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer 123:2642–2650PubMedCrossRefGoogle Scholar
  108. Hughes MS, Yu YY, Dudley ME, Zheng Z, Robbins PF, Li Y, Wunderlich J, Hawley RG, Moayeri M, Rosenberg SA, Morgan RA (2005) Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene Ther 16:457–472PubMedPubMedCentralCrossRefGoogle Scholar
  109. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698–2703PubMedPubMedCentralCrossRefGoogle Scholar
  110. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, Ohno T (2004) Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 24:1861–1871PubMedGoogle Scholar
  111. Iwai Y, Hamanishi J, Chamoto K, Honjo T (2017) Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci 24:26.  https://doi.org/10.1186/s12929-017-0329-9CrossRefPubMedPubMedCentralGoogle Scholar
  112. Jayashankar R, Chaudhuri MK, Singh O, Alam A, Talwar GP (1989) Semisynthetic anti-LHRH vaccine causing atrophy of the prostate. Prostate 14:3–11PubMedCrossRefGoogle Scholar
  113. Junco JA, Basalto R, Fuentes F, Bover E, Reyes O, Pimentel E, Calzada L, Castro MD, Arteaga N, López Y, Hernández H, Bringas R, Garay H, Peschke P, Bertot J, Guillén G (2008) Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms. Adv Exp Med Biol 617:581–587PubMedCrossRefGoogle Scholar
  114. June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117:1466–1476PubMedPubMedCentralCrossRefGoogle Scholar
  115. Kahn M, Sugawara H, McGowan P, Okuno K, Nagoya S, Hellström KE, Hellström I, Greenberg P (1991) CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 146:3235–3241PubMedGoogle Scholar
  116. Kalantarov G, Acevedo HF (1998) Demonstration of dose dependent cytotoxic activity in cancer cells by specific human chorionic gonadotropin monoclonal antibodies. Cancer 83:783–787PubMedCrossRefGoogle Scholar
  117. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73.  https://doi.org/10.1126/scitranslmed.3002842CrossRefPubMedPubMedCentralGoogle Scholar
  118. Kanojia D, Garg M, Gupta S, Gupta A, Suri A (2011) Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am J Pathol 178:1009–1020PubMedPubMedCentralCrossRefGoogle Scholar
  119. Kanojia D, Garg M, Saini S, Agarwal S, Parashar D, Jagadish N, Seth A, Bhatnagar A, Gupta A, Kumar R, Lohiya NK, Suri A (2013) Sperm associated antigen 9 plays an important role in bladder transitional cell carcinoma. PLoS One 8:e81348PubMedPubMedCentralCrossRefGoogle Scholar
  120. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099–1105PubMedPubMedCentralCrossRefGoogle Scholar
  121. Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK, Jäger E (2010) Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer 126:909–918PubMedGoogle Scholar
  122. Kaufman HL, Kohlhapp FJ, Zloza A (2015) Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14:642–662PubMedCrossRefGoogle Scholar
  123. Kavecansky J, Pavlick AC (2017) Beyond checkpoint inhibitors: the next generation of immunotherapy in oncology. AJHO 13:9–20Google Scholar
  124. Kawamura T, Takeda K, Mendiratta SK, Kawamura H, Van Kaer L, Yagita H, Abo T, Okumura K (1998) Critical role of NK1+ T cells in IL-12-induced immune responses in vivo. J Immunol 160:16–19PubMedGoogle Scholar
  125. Khare P, Bose A, Singh P, Singh S, Javed S, Jain SK, Singh O, Pal R (2017) Gonadotropin and tumorigenesis: Direct and indirect effects on inflammatory and immunosuppressive mediators and invasion. Mol Carcinog 56:359–370PubMedCrossRefGoogle Scholar
  126. Kimura H, Yamaguchi Y (1997) A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 80:42–49PubMedCrossRefGoogle Scholar
  127. Kitadani J, Ojima T, Iwamoto H, Tabata H, Nakamori M, Nakamura M, Hayata K, Katsuda M, Miyajima M, Yamaue H (2018) Cancer vaccine therapy using carcinoembryonic antigen - expressing dendritic cells generated from induced pluripotent stem cells. Sci Rep 8:4569.  https://doi.org/10.1038/s41598-018-23120-zCrossRefPubMedPubMedCentralGoogle Scholar
  128. Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M (2013) Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol 31:71–75PubMedCrossRefGoogle Scholar
  129. Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Düwell P, Zeng Y, Schmollinger JC, Schnurr M, Endres S, Rothenfußer S (2015) Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. J Natl Cancer Inst 23:107(8).  https://doi.org/10.1093/jnci/djv146CrossRefGoogle Scholar
  130. Kolb HJ, Mittermüller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465PubMedCrossRefGoogle Scholar
  131. Koyama Y, Ito T, Hasegawa A, Eriguchi M, Inaba T, Ushigusa T, Sugiura K (2016) Exosomes derived from tumor cells genetically modified to express Mycobacterium tuberculosis antigen: a novel vaccine for cancer therapy. Biotechnol Lett 38:1857–1866PubMedCrossRefGoogle Scholar
  132. Krummel MF, Allison JP (1996) CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533–2540PubMedCrossRefGoogle Scholar
  133. Ku CC, Murakami M, Sakamoto A, Kappler J, Marrack P (2000) Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 288:675–678PubMedCrossRefGoogle Scholar
  134. Kuppuswamy M, Spencer JF, Doronin K, Tollefson AE, Wold WS, Toth K (2005) Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther 12:1608–1617PubMedCrossRefGoogle Scholar
  135. Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, Gratama JW (2013) Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 21:904–912PubMedPubMedCentralCrossRefGoogle Scholar
  136. Lane D, Levine A (2010) p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2:a000893PubMedPubMedCentralGoogle Scholar
  137. Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, Gregson B, Rivers P, Vonderheide RH, Liebowitz DN, Porter DL, June CH (2003) Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood 102:2004–2013PubMedCrossRefGoogle Scholar
  138. Lardone RD, Chan AA, Lee AF, Foshag LJ, Faries MB, Sieling PA, Lee DJ (2017) Mycobacterium bovis Bacillus Calmette-Guérin alters melanoma microenvironment favoring antitumor T cell responses and improving M2 macrophage function. Front Immunol. 8:965.  https://doi.org/10.3389/fimmu.2017.00965CrossRefPubMedPubMedCentralGoogle Scholar
  139. Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188–195PubMedPubMedCentralCrossRefGoogle Scholar
  140. Li Q, Carr AL, Donald EJ, Skitzki JJ, Okuyama R, Stoolman LM, Chang AE (2005a) Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T-cell responses towards a type 1 pattern. Cancer Res 65:1063–1070PubMedGoogle Scholar
  141. Li Y, Bleakley M, Yee C (2005b) IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 175:2261–2269PubMedCrossRefGoogle Scholar
  142. Li H, Peng Y, Niu H, Wu B, Zhang Y, Zhang Y, Bai X, He P (2014) SPAG9 is overexpressed in human prostate cancer and promotes cancer cell proliferation. Tumour Biol 35:6949–6954PubMedCrossRefGoogle Scholar
  143. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC (2014) Going viral with cancer immunotherapy. Nat Rev Cancer 14:559–567PubMedCrossRefGoogle Scholar
  144. Lin CL, Lo WF, Lee TH, Ren Y, Hwang SL, Cheng YF, Chen CL, Chang YS, Lee SP, Rickinson AB, Tam PKH (2002) Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 62:6952–6958PubMedGoogle Scholar
  145. Lipson EJ, Sharfman WH, Chen S, McMiller TL, Pritchard TS, Salas JT, Mergenthaler S, Freed I, Ravi S, Wang H, Luber B, Sproul JD, Taube JM, Pardoll DM, Topalian SL (2015) Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J Transl Med 63:883–885Google Scholar
  146. Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL (2015) 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 21:581–590PubMedPubMedCentralCrossRefGoogle Scholar
  147. Longo DL (2010) New therapies for castration-resistant prostate cancer. N Engl J Med 363:479–481PubMedCrossRefGoogle Scholar
  148. Lu Y, Bellgrau D, Dwyer-Nield LD, Malkinson AM, Franzusoff A (2004) Mutation-selective tumor remission with ras-targeted, whole yeast-based immunotherapy. Cancer Res 64:5084–5088PubMedCrossRefGoogle Scholar
  149. Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 6:3689–3697Google Scholar
  150. Madan RA, Arlen PM, Mahsa M, Hodge JW, Gulley JL (2009) Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 18:1001–1011PubMedPubMedCentralCrossRefGoogle Scholar
  151. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwuck R, Humblet Y, Canon J-L, Laurent C, Naeyaert J-M, Plagne R, Deraemaeker R, Knuth A, Jager E, Brasseur F, Herman J, Couiae PG, Boon T (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883–885PubMedCrossRefGoogle Scholar
  152. Markley JC, Sadelain M (2010) IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115:3508–3519PubMedPubMedCentralCrossRefGoogle Scholar
  153. Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y (2000) IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc Natl Acad Sci USA 97:11445–11450PubMedCrossRefGoogle Scholar
  154. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051–3057PubMedCrossRefPubMedCentralGoogle Scholar
  155. Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR, Wunderlich JR, Hughes MS, Restifo NP, Rosenberg SA (2003) High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immunol 171:3287–3295PubMedPubMedCentralCrossRefGoogle Scholar
  156. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL (2002) Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin Cancer Res 8:2044–2051PubMedGoogle Scholar
  157. Moutzouris G, Yannopoulos D, Barbatis C, Zaharof A, Theodorou C (1993) Is beta-human chorionic gonadotrophin production by transitional cell carcinoma of the bladder a marker of aggressive disease and resistance to radiotherapy? Br J Urol 72:907–909PubMedCrossRefGoogle Scholar
  158. Munguia A, Ota T, Miest T, Russell SJ (2008) Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther 15:797–806PubMedCrossRefGoogle Scholar
  159. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A (1996) Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29:371–380PubMedCrossRefGoogle Scholar
  160. Muul LM, Spiess PJ, Director EP, Rosenberg SA (1987) Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138:989–995PubMedGoogle Scholar
  161. Nakamura T, Peng KW, Harvey M, Greiner S, Lorimer IA, James CD, Russell SJ (2005) Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23:209–214PubMedCrossRefGoogle Scholar
  162. Neelapu SS, Munshi NC, Jagannath S, Watson TM, Pennington R, Reynolds C, Barlogie B, Kwak LW (2005) Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma. Bone Marrow Transplant 36:315–323PubMedCrossRefPubMedCentralGoogle Scholar
  163. Neumatis J, Dillman RO, Schwarzenberger P, Senzer N, Fakhrai H (2006) Phase II study of Belagenpumatucel-L, a transforming growth factor beta-2 antisense gene modified allogenic tumor cell vaccine in non-small–cell lung cancer. J Clin Oncol 24:4721–4730CrossRefGoogle Scholar
  164. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Bélec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, Shore GC (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A. 104:19512–19517PubMedPubMedCentralCrossRefGoogle Scholar
  165. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8:1369–1375PubMedCrossRefGoogle Scholar
  166. Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, Nakui M, Sato T, Habu S, Tashiro H, Sato M, Ohta A (1999) Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 190:617–627PubMedPubMedCentralCrossRefGoogle Scholar
  167. Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, Bouchier-Hayes L, Savoldo B, Dotti G (2014) Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res 74:5195–5205PubMedPubMedCentralCrossRefGoogle Scholar
  168. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett D, Brown C, Zeh H, Holtzman M, Reinhart T, Whiteside T, Butterfield LH, Hamilton R, Potter DM, Pollack IF, Salazar AMF, Lieberman S (2011) Induction of cd8+ t-cell responses against novel glioma–associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:330–336PubMedCrossRefGoogle Scholar
  169. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O’Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677–681PubMedCrossRefGoogle Scholar
  170. Osborne C, Wilson P, Tripathy D (2004) Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 9:361–377PubMedCrossRefGoogle Scholar
  171. Oudard S, Rixe O, Beuselinck B, Linassier C, Banu E, Machiels JP, Baudard M, Ringeisen F, Velu T, Lefrere-Belda MA, Limacher JM, Fridman WH, Azizi M, Acres B, Tartour E (2011) A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother 60:261–271PubMedCrossRefPubMedCentralGoogle Scholar
  172. Pal R, Singh O (2001) Absence of corpus luteum rescue by chorionic gonadotropin in women immunized with a contraceptive vaccine. Fertil Steril 76:332–336PubMedCrossRefGoogle Scholar
  173. Pal R, Singh O, Rao LV, Talwar GP (1990) Bioneutralization capacity of the antibodies generated in women by the beta subunit of human chorionic gonadotropin (bhCG) and bhCG associated with alpha subunit of ovine luteinizing hormone linked to carriers. Am J Reprod Immunol 22:124–126PubMedCrossRefPubMedCentralGoogle Scholar
  174. Parkin DM (2006) The global health burden of infection associated cancers in the year 2002. Int J Cancer 118:3030–3044PubMedCrossRefPubMedCentralGoogle Scholar
  175. Parks R, Evelegh C, Graham F (1999) Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 6:1565–1573PubMedCrossRefGoogle Scholar
  176. Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14:847–856PubMedCrossRefGoogle Scholar
  177. Patnaik A, Socinski MA, Gubens MA, Gandhi L, Stevenson J, Bachman RD, Bourque J, Ge JY, Im E, Gadgeel SM (2015) Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 33:15_suppl 8011-8011Google Scholar
  178. Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP (2007) Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 117:2197–2204PubMedPubMedCentralCrossRefGoogle Scholar
  179. Perna SK, De Angelis B, Pagliara D, Hasan ST, Zhang L, Mahendravada A, Heslop HE, Brenner MK, Rooney CM, Dotti G, Savoldo B (2013) Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: Implications for adoptive T cell-based therapies for lymphoma. Clin Can Res 19:106–117CrossRefGoogle Scholar
  180. Powell DJ Jr, Dudley ME, Robbins PF, Rosenberg SA (2005) Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105:241–250PubMedCrossRefGoogle Scholar
  181. Pulè MA, Straathof KC, Dotti G, Heslop HE, Rooney CM, Brenner MK (2005) A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther 12:933–941PubMedCrossRefGoogle Scholar
  182. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264–1270PubMedPubMedCentralCrossRefGoogle Scholar
  183. Quesada JR, Gutterman JU (1986) Alpha interferons in B-cell neoplasms. Br J Haematol 64:639–646PubMedCrossRefGoogle Scholar
  184. Quezada SA, Peggs KS, Curran MA, Allison JP (2006) CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest 116:1935–1945PubMedPubMedCentralCrossRefGoogle Scholar
  185. Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher JM (2016) TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol 17:212–223PubMedCrossRefGoogle Scholar
  186. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Lévy E, Krzakowski M, Hess D, Tartour E, Chenard MP, Limacher JM, Bizouarne N, Acres B, Halluard C, Velu T (2008) A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 3:735–744PubMedCrossRefGoogle Scholar
  187. Ratliff T, Ritchey J, Yuan J, Andriole G, Catalona W (1993) T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150:1018–1023PubMedCrossRefGoogle Scholar
  188. Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nanterl SH, O’Reilly SO, Shepherd JD, Sutherland HJ, Voss N, Chan KW, Philips GL (1994) Intensive therapy with cyclophosphamide, carmustine, etoposide+-cisplatin, and autologous bone marrow transplantation for Hodgkin’s disease in first relapse after combination chemotherapy. Blood 83:1193–1199PubMedCrossRefGoogle Scholar
  189. Reed JC, Pellecchia M (2005) Apoptosis-based therapies for hematologic malignancies. Blood 106:408–418PubMedCrossRefGoogle Scholar
  190. Ren XW, Liang M, Meng X, Ye X, Ma H, Zhao Y, Guo J, Cai N, Chen HZ, Ye SL, Hu F (2006) A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Cancer Gene Ther 13:159–168PubMedCrossRefGoogle Scholar
  191. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP, Robert C (2016) Association of Pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315:1600–1609PubMedCrossRefGoogle Scholar
  192. Rice J, Ottensmeier CH, Stevenson FK (2008) DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8:108–120PubMedCrossRefGoogle Scholar
  193. Rivera RT, Pasion SG, Wong DT, Fei YB, Biswas DK (1989) Loss of tumorigenic potential by human lung tumor cells in the presence of antisense RNA specific to the ectopically synthesized alpha subunit of human chorionic gonadotropin. J Cell Biol 108:2423–2434PubMedCrossRefGoogle Scholar
  194. Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517–2526PubMedCrossRefGoogle Scholar
  195. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330PubMedCrossRefGoogle Scholar
  196. Romano E, Rossi M, Ratzinger G, de Cos MA, Chung DJ, Panageas KS, Wolchok JD, Houghton AN, Chapman PB, Heller G, Yuan J, Young JW (2011) Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res 17:1984–1997PubMedPubMedCentralCrossRefGoogle Scholar
  197. Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, Musiek A, Schaffer A, Anadkat MJ, Rosman I, Miller D, Egan JO, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood 131:2515–2527PubMedPubMedCentralCrossRefGoogle Scholar
  198. Rosenberg SA, Spiess P, Lafreniere RA (1986) New approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318–1321PubMedCrossRefGoogle Scholar
  199. Rosenberg SA, Sportes C, Ahmadzadeh M, Fry TJ, Ngo LT, Schwarz SL, Stetler-Stevenson M, Morton KE, Mavroukakis SA, Morre M et al (2006) IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 29:313–319PubMedPubMedCentralCrossRefGoogle Scholar
  200. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550–4557PubMedPubMedCentralCrossRefGoogle Scholar
  201. Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D (2011) Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 117:393–402PubMedPubMedCentralCrossRefGoogle Scholar
  202. Ruan Z, Yang Z, Wang Y, Wang H, Chen Y, Shang X, Yang C, Guo S, Han J, Liang H, Wu Y (2009) DNA vaccine against tumor endothelial marker 8 inhibits tumor angiogenesis and growth. J Immunother 32:486–491PubMedCrossRefGoogle Scholar
  203. Russell SJ, Peng K-W, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30:1–13CrossRefGoogle Scholar
  204. Sachdeva R, Bhardwaj N, Huhtaniemi I, Aggrawal U, Jain SK, Zaidi R, Singh O, Pal R (2012) Transgenesis-mediated reproductive dysfunction and tumorigenesis: effects of immunological neutralization. PLoS One 7(11):e51125PubMedPubMedCentralCrossRefGoogle Scholar
  205. Sahoo S, Singh P, Kalha B, Singh O, Pal R (2015) Gonadotropin-mediated chemoresistance: Delineation of molecular pathways and targets. BMC Cancer 15:931.  https://doi.org/10.1186/s12885-015-1938-xCrossRefPubMedPubMedCentralGoogle Scholar
  206. Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, Baron-Bodo V, Mallard E, Bartholeyns J, Goxe B, Latour N, Leroy S, Prigent D, Martiat P, Sales F, Laporte M, Bruyns C, Romet-Lemonne JL, Abastado JP, Lehmann F, Velu T (2006) Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother 55:819–829PubMedCrossRefGoogle Scholar
  207. Santoro SP, Kim S, Motz GT, Alatzoglou D, Li C, Irving M, Powell DJ Jr, Coukos G (2015) T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol Res 3:68–84PubMedCrossRefGoogle Scholar
  208. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121:1822–1826PubMedPubMedCentralCrossRefGoogle Scholar
  209. Sayem MA, Tomita Y, Yuno A, Hirayama M, Irie A, Tsukamoto H, Senju S, Yuba E, Yoshikawa T, Kono K, Nakatsura T, Nishimura Y (2015) Identification of glypican-3-derived long peptides activating both CD8+ and CD4+ T cells; prolonged overall survival in cancer patients with Th cell response. Oncoimmunology 5:e1062209PubMedPubMedCentralCrossRefGoogle Scholar
  210. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889–1894PubMedPubMedCentralCrossRefGoogle Scholar
  211. Scheiermann J, Klinman DM (2014) Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer. Vaccine 32:6377–6389PubMedPubMedCentralCrossRefGoogle Scholar
  212. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195:1279–1288PubMedPubMedCentralCrossRefGoogle Scholar
  213. Shelley MD, Mason MD, Kynaston H (2010) Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses. Cancer Treat Rev 36:195–205PubMedCrossRefGoogle Scholar
  214. Shen X, Zhou J, Hathcock KS, Robbins P, Powell DJ Jr, Rosenberg SA, Hodes RJ (2007) Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother 30:123–129PubMedPubMedCentralCrossRefGoogle Scholar
  215. Simms MS, Scholfield DP, Jacobs E, Michaeli D, Broome P, Humphreys JE, Bishop MC (2000) Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. Br J Cancer 83:443–446PubMedPubMedCentralCrossRefGoogle Scholar
  216. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ (2005) Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615–625PubMedCrossRefGoogle Scholar
  217. Singh O, Rao LV, Gaur A, Sharma NC, Alam A, Talwar GP (1989) Antibody response and characteristics of antibodies in women immunized with three contraceptive vaccines inducing antibodies against human chorionic gonadotropin. Fertil Steril 52:739–744PubMedCrossRefGoogle Scholar
  218. Singh M, Das SK, Suri S, Singh O, Talwar GP (1998) Regain of fertility and normality of progeny born during below protective threshold antibody titers in women immunized with the HSD-hCG vaccine. Am J Reprod Immunol 39:395–398PubMedCrossRefGoogle Scholar
  219. Sloots A, Mastini C, Rohrbach F, Weth R, Curcio C, Burkhardt U, Jager E, Forni G, Cavallo F, Wels WS (2008) DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma. Clin Cancer Res 14:6933–6943PubMedCrossRefGoogle Scholar
  220. Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD (1999) Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5:1738–1744PubMedGoogle Scholar
  221. Smith DA, Conkling P, Richards DA, Nemunaitis JJ, Boyd TE, Mita AC, de La Bourdonnaye G, Wages D, Bexon AS (2014) Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy. Cancer Immunol Immunother 63:787–796PubMedCrossRefGoogle Scholar
  222. Sobol RE (2005) The rationale for prophylactic cancer vaccines and need for a paradigm shift. Cancer Gene Ther 13:725–731CrossRefGoogle Scholar
  223. Soussi T, Hamroun D, Hjortsberg L, Rubio-Nevado JM, Fournier JL, Beroud C (2010) MUT-TP53 2.0: a novel versatile matrix for statistical analysis of TP53 mutations in human cancer. Hum Mutat 31:1020–1025PubMedCrossRefGoogle Scholar
  224. Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115:739–746PubMedPubMedCentralCrossRefGoogle Scholar
  225. Sportès C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow C, Brown MR, Fleisher TA, Noel P, Maric I, Stetler-Stevenson M, Engel J, Buffet R, Morre M, Amato RJ, Pecora A, Mackall CL, Gress RE (2010) Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 16:727–735PubMedPubMedCentralCrossRefGoogle Scholar
  226. Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R (2006) Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 66:7694–7700PubMedCrossRefGoogle Scholar
  227. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z (1993) Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 151:6577–6582PubMedGoogle Scholar
  228. Stanford MM, Barrett JW, Nazarian SH, Werden S, McFadden G (2006) Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol 8:1251–1260Google Scholar
  229. Steele N, Anthony A, Saunders M, Esmarck B, Ehrnrooth E, Kristjansen PEG, Nihlén A, Hansen LT, Cassidy J (2012) A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. Br J Cancer 106:793–798PubMedPubMedCentralCrossRefGoogle Scholar
  230. Su Z, Dannull J, Yang BK, Dahm P, Coleman D, Yancey D, Sichi S, Niedzwiecki D, Boczkowski D, Gilboa E, Vieweg J (2005) Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 174:3798–3807PubMedCrossRefGoogle Scholar
  231. Szturmowicz M, Slodkowska J, Zych J, Rudzinski P, Sakowicz A, Rowinska-Zakrzewska E (1999) Frequency and clinical significance of beta-subunit human chorionic gonadotropin expression in non-small cell lung cancer patients. Tumour Biol 20:99–104PubMedCrossRefGoogle Scholar
  232. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356:802–807PubMedCrossRefGoogle Scholar
  233. Talwar GP, Singh O, Pal R, Chatterjee N, Sahai P, Dhall K, Kaur J, Das SK, Suri S, Buckshee K et al (1994) A vaccine that prevents pregnancy in women. Proc Natl Acad Sci U S A 91:8532–8536PubMedPubMedCentralCrossRefGoogle Scholar
  234. Talwar GP, Singh OM, Gupta SK, Hasnain SE, Pal R, Majumbar SS, Vrati S, Mukhopadhay A, Srinivasan J, Deshmukh U, Ganga S, Mandokhot A, Gupta A (1997) The HSD-hCG vaccine prevents pregnancy in women: feasibility study of a reversible safe contraceptive vaccine. Am J Reprod Immunol 37:153–160PubMedCrossRefGoogle Scholar
  235. Talwar GP, Raina K, Gupta JC, Ray R, Wadhwa S, Ali MM (2004) A recombinant luteinising-hormone-releasing-hormone immunogen bioeffective in causing prostatic atrophy. Vaccine 22:3713–3721PubMedCrossRefGoogle Scholar
  236. Talwar GP, Vyas HK, Purswani S, Gupta JC (2009) Gonadotropin-releasing hormone/human chorionic gonadotropin beta based recombinant antibodies and vaccines. J Reprod Immunol 83:158–163PubMedCrossRefGoogle Scholar
  237. Thalmensi J, Pliquet E, Liard C, Escande M, Bestetti T, Julithe M, Kostrzak A, Pailhes-Jimenez AS, Bourges E, Loustaum M, Caumartin J, Lachgar A, Huet T, Wain-Hobson S, Langlade-Demoyen P (2016) Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response. Oncoimmunology 5:e1083670.  https://doi.org/10.1080/2162402X.2015.1083670CrossRefPubMedGoogle Scholar
  238. Topalian SL, Sznol M, McDermott DF et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020–1030PubMedPubMedCentralCrossRefGoogle Scholar
  239. Trepiakas R, Pedersen AE, Met O, Svane IM (2009) Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function. Vaccine 27:2213–2219PubMedCrossRefGoogle Scholar
  240. Triozzi PL, Tuthill RJ, Borden E (2011) Re-inventing intratumoral immunotherapy for melanoma. Immunotherapy 3:653–671PubMedCrossRefGoogle Scholar
  241. Uchida H, Marzulli M, Nakano K, Goins WF, Chan J, Hong C-S, Mazzacurati L, Yoo JY, Haseley A, Nakashima H, Baek H, Kwon H, Kumagai I, Kuroki M, Kaur B, Chiocca EA, Grandi P, Cohen JB, Glorioso JC (2013) Effective treatment of an orthotopic xenograft model of human glioblastoma using an egfr- retargeted oncolytic herpes simplex virus. Mol Ther 21:561–569PubMedCrossRefGoogle Scholar
  242. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O’Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ, Ayyoub M (2007) Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104:8947–8952PubMedCrossRefGoogle Scholar
  243. Vansteenkiste JF, Cho BC, Vanakesa T, De Pas T, Zielinski M, Kim MS, Jassem J, Yoshimura M, Dahabreh J, Nakayama H, Havel L, Kondo H, Mitsudomi T, Zarogoulidis K, Gladkov OA, Udud K, Tada H, Hoffman H, Bugge A, Taylor P, Gonzalez EE, Liao ML, He J, Pujol JL, Louahed J, Debois M, Brichard V, Debruyne C, Therasse P, Altorki N (2016) Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17:822–835PubMedCrossRefGoogle Scholar
  244. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95:1459–1466PubMedPubMedCentralCrossRefGoogle Scholar
  245. Vollmer J, Krieg AM (2009) Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 61:195–204PubMedCrossRefGoogle Scholar
  246. Vongpunsawad S, Oezgun N, Braun W, Cattaneo R (2004) Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol 78:302–313PubMedPubMedCentralCrossRefGoogle Scholar
  247. Wagner H (2001) Toll meets bacterial CpG-DNA. Immunity 14:499–502PubMedCrossRefGoogle Scholar
  248. Wagner TC, Velichko S, Chesney SK, Biroc S, Harde D, Vogel D, Croze E (2004) Interferon receptor expression regulates the antiproliferative effects of interferons on cancer cells and solid tumors. Int. J. Cancer 111:32–42PubMedCrossRefGoogle Scholar
  249. Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, June C, Kaiser LR, Ling LE, Albelda SM (2008) Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res 14:3966–3974PubMedPubMedCentralCrossRefGoogle Scholar
  250. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, Pawelec G, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Frisch J, Mayer-Mokler A, Kirner A, Rammensee HG, Reinhardt C, Singh-Jasuja H (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 18:1254–1261PubMedCrossRefGoogle Scholar
  251. Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z, Liu H, Jiang G, Cheng Z, Wang S, Dong J, Feng B, Chard LS, Lemoine NR, Wang Y (2017) Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nature Commun 8:1395.  https://doi.org/10.1038/s41467-017-01385-8CrossRefGoogle Scholar
  252. Warren EH, Fujii N, Akatsuka Y, Chaney CN, Mito JK, Loeb KR, Gooley TA, Brown ML, Koo KK, Rosinski KV, Ogawa S, Matsubara A, Appelbaum FR, Riddell SR (2010) Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 15:3869–3878CrossRefGoogle Scholar
  253. Weber JS, Zarour H, Redman B, Trefzer U, O’Day S, van den Eertwegh AJ, Marshall E, Wagner S (2009) Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 115:3944–3954PubMedCrossRefGoogle Scholar
  254. Weber JS, Vogelzang NJ, Ernstoff MS, Goodman OB, Cranmer LD, Marshall JL, Miles S, Rosario D, Diamond DC, Qiu Z, Obrocea M, Bot A (2011) A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother 34:556–567PubMedPubMedCentralCrossRefGoogle Scholar
  255. Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I, Rammensee HG, Garbe C (2009) Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. J Immunother 32:498–507PubMedCrossRefGoogle Scholar
  256. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, Phase 2 trial. Lancet Oncol 15:69–77PubMedCrossRefGoogle Scholar
  257. Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, Burbridge SE, Box C, Eccles SA, Maher J (2012) Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol 32:1059–1070PubMedCrossRefGoogle Scholar
  258. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 369:122–133PubMedPubMedCentralCrossRefGoogle Scholar
  259. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino MS, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto PA, Long GV, Cebon J, Sosman J, Postow MA, Callahan MK, Walker D, Rollin L, Bhore R, Hodi FS, Larkin J (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377:1345–1356PubMedPubMedCentralCrossRefGoogle Scholar
  260. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247:1465–1468PubMedCrossRefGoogle Scholar
  261. Yan Q, Lou G, Qian Y, Qin B, Xu X, Wang Y, Liu Y, Dong X (2016) SPAG9 is involved in hepatocarcinoma cell migration and invasion via modulation of ELK1 expression. Onco Targets Ther 9:1067–1077PubMedPubMedCentralCrossRefGoogle Scholar
  262. Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, Leitner WW, Restifo NP (1999) Cancer therapy using a self-replicating RNA vaccine. Nat Med 5:823–827PubMedPubMedCentralCrossRefGoogle Scholar
  263. Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP (2014) Localised oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 6:1–14CrossRefGoogle Scholar
  264. Zhang JF, Hu C, Geng Y, Selm J, Klein SB, Orazi A, Taylor MW (1996) Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. Proc Natl Acad Sci USA 93:4513–4518PubMedCrossRefGoogle Scholar
  265. Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA (2005) Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 174:4415–4423PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Ruchi Sachdeva
    • 1
  • Poonam Singh
    • 1
  • Anjali Bose
    • 1
  • Beneeta Kalha
    • 1
  • Moumita Sarkar
    • 1
  • Rahul Pal
    • 1
    Email author
  1. 1.National Institute of ImmunologyNew DelhiIndia

Personalised recommendations